

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

AUG 24 2004
SEARCHED INDEXED
PCT/US03/03444

Sheet 1 of 10

Attorney Docket Number 60820.000004

PATENT & TRADEMARK DOCUMENTS					
*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MD	1.	US- 6,245,523	06-12-2001	ALTIERI	_____

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
MD	2.	WO	92/20356	11-26-1992	BOON, T. et al	_____	_____	_____
MD	3.	WO	94/05304	03-17-1994	BOON-FALLEUR, T., et al	_____	_____	_____
	4.	WO	97/28816	08-14-1997	JAGER, E., et al	_____	_____	_____
MD	5.	WO	00/03693	01-27-2000	LEASON, H., et al.	_____	_____	_____

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	6.	VAN DEN EYNDE, B. J. et al., "Tumor antigens recognized by T lymphocytes", Int. J. Clin. Lab. Res., 27:81-86, 1997	_____	_____
MD	7.	ROSENBERG, S. A., "Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens," J. Natl. Cancer Inst., 22:88: 1635-1644, 1996	_____	_____

EXAMINER SIGNATURE /Marianne Dibrino/ DATE CONSIDERED 03/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Application Number	10/715,417
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Filing Date	November 19, 2003
				First Named Inventor	Eivind Per Thor STRATEN et al.
				Art Unit	1646-1644
				Examiner Name	Unassigned/Marianne Dibrino/
				Sheet	2

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	8.	MARCHAND, M. et al., "T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MACE-3 and presented by HLA-A1," Int. J. Cancer, 80: 219-230, 1999	—	—
	9.	BROSSART, P. et al., "W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes," Cancer Res., 58: 732-736, 1998.	—	—
	10.	BROSSART, P. et al., "Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies," Blood, 93:4309-4317, 1999	—	—
	11.	VONDERHEIDE, R. et al., "The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes," Immunity, 10:673-679, 1999	—	—
	12.	LACASSE, E. C. et al., "The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene, 17:3247-3259, 1998	—	—
	13.	ALTIERI, D. C. et al., "Survivin apoptosis: an interloper between cell death and cell proliferation in cancer," Lab Invest, 79:1327-1333, 1999	—	—
	14.	AMBROSINI, G. et al., "Induction of apoptosis and inhibition of cell proliferation by survivin, in human melanoma," J. Invest Dermatol., 113:1076-1081, 1999	—	—
	15.	GROSSMAN, D. et al., "Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma," J. Invest Dermatol., 113: 1076-1081, 1999.	—	—
	16.	GROSSMAN, D. et al., "Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line," Lab Invest, 79: 1121-1126, 1999	—	—
MD	17.	ANDERSEN, M. H. et al., "An assay for peptide binding to HLA-Cw*0102," Tissue Antigens, 54:185-190, 1999	—	—

EXAMINER SIGNATURE /Marianne Dibrino/ DATE CONSIDERED 03/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN et al.
Art Unit	1646-1644
Examiner Name	Unassigned Marianne Dibrino/

Sheet	3	of	10	Attorney Docket Number	60820.000004
-------	---	----	----	------------------------	--------------

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	18.	ANDERSEN, M. H. et al., "Phosphorylated Peptides Can Be Transported by TAP Molecules, Presented by Class I MHC Molecules, and Recognized by Phosphopeptide-Specific CTL." J. Immunol., 163:3812-3188, 1999	—	—
	19.	MCCUTCHEON, M. et al., "A sensitive ELISPOT assay to detect low-frequency human T lymphocytes," J. Immunol. Methods, 210:149-166, 1997	—	—
	20.	PASS, H. A. et al., "Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay," Cancer J. Sci. Am., 4: 316-323, 1998	—	—
	21.	BERKE, Z. et al., "Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules," Leukemia, 14:419-426, 2000	—	—
	22.	FALK, K. et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature, 351:290-296, 1991	—	—
	23.	CORNELISON, T. L., "Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment, Curr. Opin. Oncol., 12:466-473, 2000	—	—
	24.	LEE, S. P. et al., "CTL control of EVB in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells," Immunol., 165: 573-582, 2000	—	—
	25.	SWANA, H. S. et al., "Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N. Engl. J. Med., 341: 452-453, 1999	—	—
MD	26.	SALGALLER, M. L. et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res., 55: 4972-4979, 1995	—	—

EXAMINER SIGNATURE /Marianne Dibrino/ DATE CONSIDERED 03/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN et al.
Art Unit	1640-1644
Examiner Name	Unassigned Marianne Dibrino/

Sheet 4 of 10 Attorney Docket Number 60820.000004

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	27.	SALGALLER, H. L. et. al., "Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptide," Cancer Res., 56:4749-4757, 1996	—	—
	28.	VALMORI, D. et al., "Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol., 160: 1750-1758, 1998	—	—
	29.	PARDOLL, D. H., "Cancer vaccines," Nat. Med., 4:525-531, 1998	—	—
	30.	KUGLER, A. et al., "Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids," Nat. Med., 6:332-336, 2000	—	—
	31.	BECKER, J. et al., "Accumulation of identical T cells in melanoma and vitiligo-like leukoderma," J. Invest. Dermatol., 113: 1033-1038, 1999	—	—
	32.	ROHAYEM, J. et al., "Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients," Cancer Res., 2000, Apr., 1:60; (7):1815-7., 60: 1815-1817	—	—
	33.	ADIDA, C. et al., "Prognostic significance of survivin expression in diffuse large B-cell lymphomas," Blood, 96: 1921-1925, 2000	—	—
	34.	ISLAM, A. et al., "High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma," Oncogene, 19:617-623, 2000	—	—
	35.	KAWASAKI, H., "Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer," Cancer Res., 58:5071-5074, 1998	—	—
MD	36.	SCHMITZ, M. et al., "Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides," Cancer Res., 60:4845-4849, 2000	—	—

EXAMINER SIGNATURE /Marianne Dibrino/

DATE CONSIDERED 03/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Application Number	10/715,417	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Filing Date	November 19, 2003	
				First Named Inventor	Eivind Per Thor STRATEN et al.	
				Art Unit	1046 1644	
				Examiner Name	Unassigned Marianne Dibrino/	
Sheet	5	of	10	Attorney Docket Number	60820.000004	
NON-PATENT LITERATURE DOCUMENTS						
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				TRANSLATION
MD	37.	ANDERSEN, M. H. et al., "Identification of a Cytotoxic T Lymphocyte Response to the Apoptosis inhibitor Protein Survivin in Cancer Patients," Cancer Res., 61:869-872, 2001				YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
	38.	LEE, K. H. et al., "Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination," J. Immunol., 161: 4183-4194, 1998				YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
	39.	ROSENBERG, S. A. et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma," Nat. Med., 4: 321-327, 1998				YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
	40.	ALTMAN, J. D. et al., "Phenotypic analysis of antigen-specific T lymphocytes," Science, 274: 94-96, 1996				YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
	41.	SCHRAMA, D. et al., "Oligoclonal I-Cell Receptor Usage Of Melanocyte Differentiation Antigen-reactive I Cells in Stage IV Melanoma Patients," Cancer Res., 61: 493-496, 2001				YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
	42.	LUXEMBOURG, A. T. et al., "Biomagnetic isolation of antigen-specific CD8+ T cells usable in immunotherapy," Nat. Biotechnol., 16: 281-285, 1998				YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
↓	43.	KIRKIN, A. F. et al., "Generation of human-melanoma specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines," Cancer Immunol. Immunother., 41: 71-81, 1995				YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
MD	44.	SCHEIBENBOGEN, C. et al., "A sensitive ELISPOT assay for detection of CD8+T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients," Clin. Cancer Res., 3: 221-226, 1997				YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
EXAMINER SIGNATURE /Marianne Dibrino/				DATE CONSIDERED 03/12/2007		
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>						

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN et al.
Art Unit	1644
Examiner Name	Unassigned Marianne Dibrino/

Sheet	6	of	10	Attorney Docket Number	60820.000004
-------	---	----	----	------------------------	--------------

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cto No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	45.	thor STRATEN, P. et al., "In Situ I-Cell Responses against Melanoma Comprise High Numbers of Locally Expanded I-Cell Clonotypes," J. Immunol., 163: 443-447, 1999	—	—
	46.	KESSLER, J. H. et al., "Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes In the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis," J. Exp. Med., 193: 73-88, 2001	—	—
	47.	de VRIES, T. 3., Fourkour, A., Wobbes, I., Verkroost, G., Ruiter, D. 3., and van Muijen, C. N. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions," Cancer Res., 57: 3223-3229, 1997	—	—
	48.	JAGER, E. et al., "Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo," Int. J. Cancer, 66: 470-476, 1996	—	—
	49.	CORMIER, J. N. et al., "Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy," J. Immunother., 21: 27-31, 1998	—	—
	50.	RIKER, A. et al., "Immune selection after antigen-specific immunotherapy of melanoma," Surgery, 126: 112-120, 1999	—	—
	51.	MAEURER, N. J., "Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen," J. Clin. Invest., 98: 1633-1641, 1996	—	—
	52.	GROSSMAN, D. et al., "Inhibition of melanoma tumor growth in vivo by survivin targeting," Proc. Natl. Acad. Sci. USA, 98: 635-640, 2001	—	—
MD	53.	TAMM, I. et al., "IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs," Cancer Res., 58: 5315-5320, 1998	—	—

EXAMINER SIGNATURE /Marianne Dibrino/

DATE CONSIDERED 03/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Application Number	10/715,417
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Filing Date	November 19, 2003
				First Named Inventor	Eivind Per Thor STRATEN et al.
				Art Unit	1644
				Examiner Name	Unassigned / Marianne Dibrino
Sheet	7	of	10	Attorney Docket Number	60820.000004

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	54.	MONZO, M. et al., "A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers," J. Clin. Oncol., 17: 2100-2104, 1999		
	55.	NAKAGAWARA, A., "Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities," Hum. Cell, 11: 115-124, 1998		
	56.	RENKVIST, N. et al., "A listing of human tumor antigens recognized by T cells," Cancer Immunol Immunother., 50: 3-15, 2001		
	57.	MELIEF, C. J. et al., "Strategies for immunotherapy of cancer," Adv. Immunol., 75:235-82.: 235-282, 2000		
	58.	GILBOA, E., "The makings of a tumor rejection antigen," Immunity., 11: 263-270, 1999		
	59.	LI, F. et al., "Control of apoptosis and mitotic spindle checkpoint by survivin," Nature, 396: 580-584, 1998		
	60.	ZAFFARONI, N. et al., "Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions," Drug Resist. Updat., 5: 65-72, 2002		
	61.	SHINOZAWA, I. et al., "Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies," Leuk. Res, 24: 965-970, 2000		
	62.	GRANZIERO, L. et al., "Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia," Blood, 97: 2777-2783, 2001		
MD	63.	AMBROSINI, C. et al., "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma," Nat. Med., 3: 917-921, 1997		

EXAMINER SIGNATURE /Marianne Dibrino/

DATE CONSIDERED 03/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Application Number	10/715,417
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Filing Date	November 19, 2003
				First Named Inventor	Eivind Per Thor STRATEN et al.
				Art Unit	1644
				Examiner Name	Unassigned / Marianne Dibrino
Sheet	8	of	10	Attorney Docket Number	

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	64.	ALTIERI, D. C. et al., "Validating survivin as a cancer therapeutic target," Nat. Rev. Cancer, 3: 46-54, 2003		
	65.	OLIE, R. A. et al., "A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy," Cancer Res, 60: 2805-2809, 2000		
	66.	ANDERSEN, N. H. et al., "Survivin--a universal tumor antigen," Histol. Histopathol., 17: 669-675, 2002		
	67.	ANDERSEN, N. H. et al., "Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients," Cancer Res, 61: 5964-5968, 2001		
	68.	CURRIER, J. R. et al., "A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays," J. Immunol. Methods, 260: 157-172, 2002		
	69.	ELVIN, J., Potter, C., Elliott, I., Cerundolo, V., and Townsend, A., "A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity," J. Immunol Methods, 158: 161-171, 1993		
	70.	RUPPERT, J., Sidney, J., Celis, F., Kubo, R. I., Grey, H. N., and Sette, A., "Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules," Cell, 74: 929-937, 1993		
	71.	Thor STRATEN, P., Barbed, A., Seremet, I., Saeterdal, I., Zeuthen, J., and Guldberg, P. Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE)., Biotechniques, 25: 244-250, 1998		
MD	72.	RAMMENSEE, H., Bachmann, J., Emmerich, N. P., Bachor, O. A., and Stevanovic, S., "SYFPEITHI: database for MHC ligands and peptide motifs," Immunogenetics, 50: 213-219, 1999		

EXAMINER SIGNATURE /Marianne Dibrino/

DATE CONSIDERED 03/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/715,417	
				Filing Date	November 19, 2003	
				First Named Inventor	Eivind Per Thor STRATEN et al.	
				Art Unit	1644	
				Examiner Name	Unassigned /Marianne Dibrino	
Sheet	9	of	10	Attorney Docket Number	60820.000004	
NON-PATENT LITERATURE DOCUMENTS						
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				TRANSLATION
MD	73.	SCHRAMA, D., Pedersen Ls, L. O., Keikavoussi, P., Andersen, N. H., Straten, P. P., Brocker, E. B., Kampgen, F., and Brocker, E. C., "Aggregation of antigen-specific I cells at the inoculation site of mature dendritic cells," J. Invest Dermatol., 119: 1443-1448, 2002				YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
	74.	MAHOTKA, C., Wenzel, N., Springer, F., Gabbert, H. E., and Gerharz, C. D., "Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties," Cancer Res., 59: 6097-6102, 1999				YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
	75.	HICKLIN, D. J., Marincola, F. N., and Ferrone, S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story," Mol. Med. Today, 5: 178-186, 1999				YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
	76.	SELIGER, B., Cabrera, T., Garrido, F., and Ferrone, S. HLA class I antigen abnormalities and immune escape by malignant cells," Semin. Cancer Biol., 12: 3-13, 2002				YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
	77.	SETTE, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. N., Melief, C. J., Oseroff, C., Yuan, F., and Ruppert, J., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes," J. Immunol., 153: 5586-5592, 1994				YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
	78.	MOUDGIL, K. D. and Sercarz, E. E., "Can antitumor immune responses discriminate between self and nonself?," Immunol. Today, 15: 353-355, 1994				YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
	79.	PARKHURST, M. R., Salgaller, N. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., and Kawakami, Y., "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues," J. Immunol., 157: 2539-2548, 1996				YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
MD	80.	GUICHARD, C., Zerbib, A., Le Gal, F. A., Hoebke, J., Connan, F., Choppin, J., Briand, J. P., and Guillet, J. G., "Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes," J. Med. Chem., 43: 3803-3808, 2000				YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
EXAMINER SIGNATURE			/Marianne Dibrino/		DATE CONSIDERED	03/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Application Number	10/715,417	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Filing Date	November 19, 2003	
				First Named Inventor	Eivind Per Thor STRATEN et al.	
				Art Unit	1646 1644	
				Examiner Name	Unassigned/Marianne Dibrino/	
Sheet	10	of	10	Attorney Docket Number	60820.000004	
NON-PATENT LITERATURE DOCUMENTS						
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				TRANSLATION
MD	81.	CLAY, T. M., Custer, M. C., McKee, M. D., Parkhurst, N., Robbins, P. F., Kerstann, K., Wunderlich, J., Rosenberg, S. A., and Nishimura, M. I., "Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue," <i>J. Immunol.</i> , 162: 1749-1755, 1999				YES <input type="checkbox"/>
	82.	MELIEF, C. J., van der Burg, S. H., Toes, R. E., Ossendorp, F., and Offringa, R., "Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. <i>Immunol. Rev.</i> , 188: 177-182, 2002				NO <input type="checkbox"/>
	83.	JAGER, E., Ringhoffer, M., Altmannsberger, M., Arand, M., Karbach, J., Jager, D., Oesch, F., and Knuth, A., "Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma," <i>Int. J. Cancer</i> , 71: 142-147, 1997				NO <input type="checkbox"/>
	84.	THURNER, B., Haendle, I., Roder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den, D. P., Brocker, E. B., Steinman, R. M., Enk, A., Kämpgen, E., and Schuler, G., "Vaccination with mage3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma," <i>J. Exp. Med.</i> , 190: 1669-1678, 1999				NO <input type="checkbox"/>
	85.	YEE, C., Thompson, J. A., Roche, P., Byrd, D. P., Lee, P. P., Piepkorn, N., Kenyon, K., Davis, N. N., Riddell, S. R., and Greenberg, P. D., "Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of cell-mediated vitiligo," <i>J. Exp. Med.</i> , 192: 1637-1644, 2000				NO <input type="checkbox"/>
MD	86.	SIMON, R. M., Steinberg, S. M., Hamilton, M., Hildesheim, A., Khleif, S., Kwak, L. W., Mackall, C. L., Schlom, J., Topalian, S. L., and Berzofsky, J. A., "Clinical trial designs for the early clinical development of therapeutic cancer vaccines," <i>J. Clin. Oncol.</i> , 19: 1848-1854, 2001				NO <input type="checkbox"/>
EXAMINER SIGNATURE /Marianne Dibrino/				DATE CONSIDERED 03/12/2007		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						